Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Runner

Cardiovascular disease is the leading cause of death globally, claiming around 17.9 million lives each year. Until now, it has been difficult to quantify the protective effect of physical activity, since previous studies have typically measured this using questionnaires. These methods are crude, subject to poor recall and cannot accurately record all activity that takes place throughout the day. This has made it difficult to assess whether increasing physical activity always gives an additional benefit in reducing the risk of cardiovascular disease, or if there is an upper limit on improvements to cardiovascular health from exercise.

A new, large-cohort study led by the University of Oxford has resolved this by using accelerometers (wrist-worn devices) to accurately record the activity of over 90,000 participants followed over five years. This found that physical activity is not only associated with lower risk of developing cardiovascular disease, but the greatest benefit is seen for those who are active at the highest level.

The full story is available on the University of Oxford website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.